ClinicaliQ Trial Snapshot
- Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects — Recruiting • Phase II • NCT04775706.
- A drug (sonefpeglutide) tested in patients with severe bowel disease to see if injections are safe and effective.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a randomized, double-blind, placebo-controlled, proof-of-concept (PoC), Phase 2 study to assess the safety, PK, and PD of SC administration of HM15912(sonefpeglutide) in adult subjects with SBS-associated intestinal failure (SBS-IF). Conditions: Short Bowel Syndrome Interventions: HM15912 Active, Placebo Lead Sponsor: Hanmi Pharmaceutical Company Limited Planned Enrollment: 18 participants